Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19 : a causal inference approach
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: This study aims to estimate the causal effects of oral antivirals and vaccinations in the prevention of all-cause mortality and progression to severe COVID-19 in an integrative setting with both antivirals and vaccinations considered as interventions.
METHODS: We identified hospitalized adult patients (i.e. aged 18 or above) in Hong Kong with confirmed SARS-CoV-2 infection between March 16, 2022, and December 31, 2022. An inverse probability-weighted (IPW) Andersen-Gill model with time-dependent predictors was used to address immortal time bias and produce causal estimates for the protection effects of oral antivirals and vaccinations against severe COVID-19.
RESULTS: Given prescription is made within 5 days of confirmed infection, nirmatrelvir-ritonavir is more effective in providing protection against all-cause mortality and development into severe COVID-19 than molnupiravir. There was no significant difference between CoronaVac and Comirnaty in the effectiveness of reducing all-cause mortality and progression to severe COVID-19.
CONCLUSIONS: The use of oral antivirals and vaccinations causes lower risks of all-cause mortality and progression to severe COVID-19 for hospitalized SARS-CoV-2 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 143(2024) vom: 21. März, Seite 107012 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheung, Yue Yat Harrison [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comirnaty |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ijid.2024.107012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370110021 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370110021 | ||
| 003 | DE-627 | ||
| 005 | 20240406232352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.107012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM370110021 | ||
| 035 | |a (NLM)38521448 | ||
| 035 | |a (PII)S1201-9712(24)00083-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheung, Yue Yat Harrison |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19 |b a causal inference approach |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: This study aims to estimate the causal effects of oral antivirals and vaccinations in the prevention of all-cause mortality and progression to severe COVID-19 in an integrative setting with both antivirals and vaccinations considered as interventions | ||
| 520 | |a METHODS: We identified hospitalized adult patients (i.e. aged 18 or above) in Hong Kong with confirmed SARS-CoV-2 infection between March 16, 2022, and December 31, 2022. An inverse probability-weighted (IPW) Andersen-Gill model with time-dependent predictors was used to address immortal time bias and produce causal estimates for the protection effects of oral antivirals and vaccinations against severe COVID-19 | ||
| 520 | |a RESULTS: Given prescription is made within 5 days of confirmed infection, nirmatrelvir-ritonavir is more effective in providing protection against all-cause mortality and development into severe COVID-19 than molnupiravir. There was no significant difference between CoronaVac and Comirnaty in the effectiveness of reducing all-cause mortality and progression to severe COVID-19 | ||
| 520 | |a CONCLUSIONS: The use of oral antivirals and vaccinations causes lower risks of all-cause mortality and progression to severe COVID-19 for hospitalized SARS-CoV-2 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comirnaty | |
| 650 | 4 | |a CoronaVac | |
| 650 | 4 | |a Molnupiravir | |
| 650 | 4 | |a Nirmatrelvir | |
| 650 | 4 | |a Ritonavir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Lau, Eric Ho Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Guosheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jialiang |e verfasserin |4 aut | |
| 700 | 1 | |a Cowling, Benjamin John |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Kwok Fai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 143(2024) vom: 21. März, Seite 107012 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2024 |g day:21 |g month:03 |g pages:107012 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.107012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2024 |b 21 |c 03 |h 107012 | ||